Kither Biotech: Funding, Investors & Team (Sep 2026)
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases. In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development. Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.
Kither Biotech has raised $20.4M across 1 funding round on record, the most recent a Series B of $20.4M announced in Mar 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kither Biotech Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Kither Biotech Funding Rounds
Kither Biotech Founders and Leadership Team
Contact details for the Kither Biotech team: 1 of 1 has an email address on file.
Start 14-day free trial →Kither Biotech Funding Compared to Other Biotechnology Startups
Kither Biotech's latest round of $20.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kither Biotech in Biotechnology and Torino
Companies Similar to Kither Biotech
NOUS is a biotech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical…
Yeastime's value proposition is its innovative retrofitting ultrasound technology, which accelerates…
Oraigo is a leading company in the development of innovative road safety technology, utilizing brain-computer…
FTnet is a digital platform in the pharmaceutical industry that employs advanced technology to connect…
Genoa Instruments is a cutting-edge startup focused on revolutionizing biomedical and health research using…
Resalis Therapeutics is focusing on addressing metabolic diseases by targeting a key regulator linked to…
CoRe is an Italian start-up, aimed at the study of new product and process solutions in the field of…
Established in 1999, PHSE is a leading provider of time-sensitive and temperature-controlled transport…
MOGU, an Italian-based European company, is dedicated to developing a variety of mycelium-based technologies…
A biotech business called DIAMANTE (Nano-Technologies for Autoimmune Disease) is dedicated to using plants to…
Relicta developed a water-soluble, transparent and biodegradable plastic for packaging made from fish…
Kither Biotech Funding FAQs
What does Kither Biotech do?
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases. In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development. Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.
How much funding has Kither Biotech raised?
Kither Biotech has raised $20.4M across 1 round on record. The most recent is a Series B of $20.4M announced in Mar 2022.
When did Kither Biotech last raise funding?
Kither Biotech's most recent funding round on record is a Series B of $20.4M, announced in Mar 2022.
Who is the CEO of Kither Biotech?
Vincent Metzler is listed as CEO at Kither Biotech.
Where is Kither Biotech headquartered?
Kither Biotech is based in Torino, Piemonte, Italy.
How many employees does Kither Biotech have?
Kither Biotech is in the 11-50 employee band.
How does Kither Biotech's funding compare to other Biotechnology startups?
Kither Biotech's latest round of $20.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Kither Biotech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kither Biotech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.